Login to Your Account



$640M Deal

Celgene's Purchase of Gloucester Puts a Scare in Allos Investors

By Donna Young


Tuesday, December 8, 2009
Celgene Corp. made a leap forward in its pursuit to become the global leader in hematology cancer therapies through its proposed $640 million acquisition of smallish biotech Gloucester Pharmaceuticals Inc., whose histone deacetylase inhibitor Istodax (romidepsin) last month gained FDA approval as a therapy for previously treated patients with cutaneous T-cell lymphoma (CTCL). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription